ReviewCancers2022
Nanovaccines for Cancer Prevention and Immunotherapy: An Update Review.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Personalized cancer vaccines: bridging immune-oncology and precision medicine for advanced therapeutics.Signal transduction and targeted therapy · 2026Review
- Barrier-Oriented Design of Next-Generation Polymeric Nanocarriers for Targeted Drug Delivery.Molecules (Basel, Switzerland) · 2026Review
- Bibliometric and visualized analysis of nanomedicine research trends for gastric cancer during the early 21st century.Discover nano · 2026Review
- Nanovaccines for lung cancer: Platforms, mechanistic insights, and translational challenges.Chinese medical journal pulmonary and critical care medicine · 2026Review
- From bench to bedside: Unveiling the background and benefits of nanovaccines tested in clinics.Asian journal of pharmaceutical sciences · 2026Review
- Next-generation nanomedicine for cancer therapy: advances, challenges, and future perspectives.Frontiers in chemistry · 2026Review
- Nanovaccines in hepatocellular carcinoma: a new frontier in cancer immunotherapy.Medical oncology (Northwood, London, England) · 2025Review
- mRNA Vaccines in Cancer Immunotherapy: Recent Advances, Clinical Translation, and Future Perspectives.Current medical science · 2025Review
- A Comprehensive Review of Nanoadjuvants in Cancer Vaccines and Their Immunomodulatory Role and Clinical Applications.Archives of Razi Institute · 2025Review
- Review
- Advances in cancer nanovaccines: a focus on colorectal cancer.Nanomedicine (London, England) · 2025Review
- Cancer Vaccines and Beyond: The Transformative Role of Nanotechnology in Immunotherapy.Pharmaceutics · 2025Review
- Nano-Oncologic Vaccine for Boosting Cancer Immunotherapy: The Horizons in Cancer Treatment.Nanomaterials (Basel, Switzerland) · 2025Review
- Nanotechnology and nanobots unleashed: pioneering a new era in gynecological cancer management - a comprehensive review.Cancer chemotherapy and pharmacology · 2025Review
- Nanotechnology Integrated Innovative Drug Delivery and Therapy for Cancer.Current pharmaceutical biotechnology · 2025Review
- New horizons in cancer immunotherapy: The evolving role of R848 and R837 (Review).Molecular and clinical oncology · 2025Review
- Prospects of nanotechnology and natural products for cancer and immunotherapy.Beilstein journal of nanotechnology · 2025Review
- Double-layered protein nanoparticles conjugated with truncated flagellin induce improved mucosal and systemic immune responses in mice.Nanoscale horizons · 2024Article
- Precision Nanovaccines for Potent Vaccination.JACS Au · 2024Review
- Gold nanostructures in melanoma: Advances in treatment, diagnosis, and theranostic applications.Heliyon · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Cancer immunotherapy has received more and more attention from cancer researchers over the past few decades. Various methods such as cell therapy, immune checkpoint blockers, and cancer vaccines alone or in combination therapies have achieved relatively satisfactory results in cancer therapy. Among these immunotherapy-based methods, cancer vaccines alone have not yet had the necessary efficacy in the clinic. Therefore, nanomaterials have increased the efficacy and ef-fectiveness of cancer vaccines by increasing their half-life and durability, promoting tumor mi-croenvironment (TME) reprogramming, and enhancing their anti-tumor immunity with minimal toxicity. In this review, according to the latest studies, the structure and different types of nanovaccines, the mechanisms of these vaccines in cancer treatment, as well as the advantages and disadvantages of these nanovaccines are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.